We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-0.46%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$23.5M
(+17%)
Cap. Flow
+$24.2M
Cap. Flow
% of AUM
15.17%
Top 10 Holdings %
Top 10 Hldgs %
62.97%
Holding
41
New
12
Increased
6
Reduced
13
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SHPG
Shire pic
SHPG
|
+$20.1M |
| 2 |
TLGT
Teligent, Inc
TLGT
|
+$7.87M |
| 3 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$7.2M |
| 4 |
Cigna
CI
|
+$6.26M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CMRX
Chimerix, Inc.
CMRX
|
+$6.85M |
| 2 |
uniQure
QURE
|
+$5.47M |
| 3 |
Centene
CNC
|
+$4.97M |
| 4 |
RXDX
Ignyta, Inc.
RXDX
|
+$4.58M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$4.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.75% |
| 2 | Real Estate | 6.42% |
| 3 | Consumer Discretionary | 4.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $21.8M | 13.69% |
+146,114
| New | +$20.1M |
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $16M | 10.01% |
94,800
-3,200
| -3% | -$537K |
|
3
MacroGenics
MGNX
$235M
| $11.2M | 7.02% |
445,000
-162,696
| -27% | -$3.95M |
|
4
Sabra Healthcare REIT
SBRA
$5.64B
| $10.2M | 6.42% |
580,000
+177,943
| +44% | +$3.14M |
|
|
AKAO
5
DELISTED
Achaogen Inc
AKAO
| $8.56M | 5.37% |
661,054
+90,134
| +16% | +$1.02M |
|
|
TLGT
6
DELISTED
Teligent, Inc
TLGT
| $8.31M | 5.21% |
+247,256
| New | +$7.87M |
|
|
AFAM
7
DELISTED
Almost Family Inc
AFAM
| $7.56M | 4.74% |
135,000
+44,452
| +49% | +$2.56M |
|
|
RETA
8
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.11M | 3.83% |
297,750
+124,853
| +72% | +$3.21M |
|
|
9
Cigna
CI
$76.6B
| $5.4M | 3.39% |
+32,200
| New | +$6.26M |
|
|
SRRA
10
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.25M | 3.3% |
+63,463
| New | +$7.2M |
|
|
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $5.23M | 3.28% |
17,695
-4,931
| -22% | -$1.46M |
|
|
12
BioMarin Pharmaceuticals
BMRN
$11.5B
| $5.14M | 3.22% |
+63,400
| New | +$5.44M |
|
13
DexCom
DXCM
$27.6B
| $4.82M | 3.02% |
260,000
+135,208
| +108% | +$2M |
|
|
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.76M | 2.98% |
+120,400
| New | +$4.68M |
|
|
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
| $4.75M | 2.98% |
59,318
-23,076
| -28% | -$3.15M |
|
|
PVLA
16
Palvella Therapeutics
PVLA
$1.98B
| $3.85M | 2.41% |
+7,047
| New | +$4.36M |
|
|
17
Iovance Biotherapeutics
IOVA
$2.23B
| $3.55M | 2.22% |
209,842
-297,010
| -59% | -$4.5M |
|
18
PUT
Inogen
INGN
$167M
| $3.29M | 2.06% |
+26,800
| New | +$3.27M |
|
|
QTNT
19
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $3.21M | 2.02% |
17,055
-6,258
| -27% | -$1.13M |
|
|
AVEO
20
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $3.03M | 1.9% |
104,355
-1,414
| -1% | -$41.4K |
|
|
CLVS
21
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.64M | 1.66% |
+50,000
| New | +$2.92M |
|
|
CIVI
22
DELISTED
Civitas Solutions, Inc.
CIVI
| $2.53M | 1.59% |
+164,396
| New | +$2.5M |
|
|
23
Centene
CNC
$31.3B
| $2.5M | 1.57% |
46,750
-95,250
| -67% | -$4.97M |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.43M | 1.52% |
46,001
+6,001
| +15% | +$350K |
|
|
PRTK
25
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.93M | 1.21% |
148,682
-29,771
| -17% | -$443K |
|
Similar funds
PL
BFC
DCM
SAM
CBB
AIG
FFWA
CIP
Prosight Management's Q1 2018 Portfolio in Review
As of Q1 2018, Prosight Management held 41 positions worth $159M, up 17% from $136M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Prosight Management deployed $24.2M of net new capital in Q1 2018, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was Shire pic: 146,114 shares worth $21.8M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 79% a quarter earlier, followed by Real Estate and Consumer Discretionary.
On the sell side, the largest reduction was uniQure, an estimated $5.47M trimmed.
- Prosight Management's largest Q1 2018 buy was Shire pic: 146,114 shares worth $21.8M.
- Prosight Management added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018, an estimated $3.21M increase.
- Prosight Management's biggest Q1 2018 reduction was uniQure, cutting an estimated $5.47M.
- Prosight Management fully exited Chimerix, Inc. in Q1 2018, selling an estimated $6.85M.
- Prosight Management's ten largest holdings make up 63% of its $159M portfolio in Q1 2018.
- Prosight Management opened 12 new positions and closed 10 in Q1 2018.
- Prosight Management's portfolio value rose 17% quarter-over-quarter to $159M.
Based on Prosight Management's 13F filing for Q1 2018, filed 14 May 2018.